Physician profile
Michael A Redmond
NPI 1821059213
$24,193.40
in general payments reported to CMS, 2019-2025
30 companies · $1,108 in 2025
The $1,108 reported for 2025 was more than what 79% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $2,009 · 2021: $5,514 · 2022: $1,052 · 2023: $1,315 · 2024: $1,242 · 2025: $1,108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,643 · Entertainment: $22.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,643.35 |
| Entertainment | $22.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $15,245.01 | 2019-2021 | |
| Alcon Vision LLC | $3,887.39 | 2019-2025 | Lensx, Clareon, Argos |
| Ivantis, INC | $1,074.31 | 2019-2021 | |
| Glaukos Corporation | $829.68 | 2019-2025 | Idosetr, Idose |
| Johnson & Johnson Surgical Vision, INC. | $682.84 | 2019-2025 | Tecnis Iol, Tecnis Simplicity, Catalys System |
| New World Medical,INC. | $389.91 | 2023 | |
| Sight Sciences, INC. | $325.87 | 2020-2025 | Omni Surgical System, Sion Surgical Instrument |
| Rxsight INC | $247.64 | 2022 | |
| Abbvie INC. | $247.17 | 2022-2025 | |
| Allergan, INC. | $225.43 | 2019-2022 | |
| Biotissue Holdings INC. | $224.10 | 2025 | |
| Genentech USA, INC. | $205.86 | 2023-2024 | Vabysmo |
| Sun Pharmaceutical Industries INC. | $128.92 | 2019-2020 | |
| Iridex Corporation | $79.79 | 2022 | |
| Apellis Pharmaceuticals, INC. | $49.70 | 2023-2024 | Syfovre |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $44.63 | 2024-2025 | Dextenza |
| Horizon Therapeutics Plc | $35.68 | 2023 | Tepezza |
| Amgen INC. | $33.82 | 2025 | Tepezza |
| Novartis Pharmaceuticals Corporation | $25.17 | 2019-2020 | |
| Shire North American Group INC | $24.73 | 2019 | |
| Mallinckrodt Hospital Products INC. | $23.66 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $23.07 | 2019 | |
| Merz Pharmaceuticals, LLC | $22.82 | 2022 | |
| Nova Eye, INC. | $22.00 | 2025 | |
| Omeros Corporation | $17.38 | 2019 | |
| Oyster Point Pharma, INC. | $17.33 | 2023 | Tyrvaya |
| Biogen, INC. | $16.05 | 2024 | Byooviz |
| Astellas Pharma US INC | $15.01 | 2023 | |
| Harrow Eye, LLC | $14.62 | 2024 | Vevye |
| Tarsus Pharmaceuticals, INC. | $13.81 | 2025 | Xdemvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Redmond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.